Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Sangamo Therapeutics is a clinical-stage biotechnology company that has been a long-standing pioneer in the field of genomic medicine, primarily focusing on its proprietary zinc finger (ZF) protein technology for gene editing, gene therapy, and gene regulation.</li>
  <li>The company faces a critical financial situation, having filed for Chapter 11 bankruptcy in June 2026 to facilitate the sale of its assets. Eli Lilly and Astellas have emerged as initial bidders for key platforms and programs, highlighting the underlying value of its technology despite the company's financial distress.</li>
  <li>Financially, Sangamo has a history of significant net losses and negative cash flow, driven by substantial R&amp;D investments. Recent years have seen declining revenues, termination of key partnerships with large pharmaceutical companies, and a failure to bring a product to market, culminating in its bankruptcy filing.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Sangamo Therapeutics is a clinical-stage biotechnology company that has been a long-standing pioneer in the field of genomic medicine, primarily focusing on its proprietary zinc finger (ZF) protein technology for gene editing, gene therapy, and gene regulation.
  The company faces a critical financial situation, having filed for Chapter 11 bankruptcy in June 2026 to facilitate the sale of its assets. Eli Lilly and Astellas have emerged as initial bidders for key platforms and programs, highlighting the underlying value of its technology despite the company's financial distress.
  Financially, Sangamo has a history of significant net losses and negative cash flow, driven by substantial R&amp;D investments. Recent years have seen declining revenues, termination of key partnerships with large pharmaceutical companies, and a failure to bring a product to market, culminating in its bankruptcy filing.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Sangamo Biosciences (SGMO US) - Aug 2026

United States

Sangamo BioSciences, Inc. researches and develops transcription factors in the regulation of genes.  These transcription factors are the proteins that turn genes on and off and regulate gene expression by recognizing specific DNA sequences.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Sangamo Biosciences (SGMO US) - Aug 2026

Sangamo Therapeutics is a clinical-stage biotechnology company that has been a long-standing pioneer in the field of genomic medicine, primarily...

αSK Primers